更新于：2024-12-09
Desonide
地奈德
更新于：2024-12-09
概要
基本信息
药物类型 小分子化药 |
别名 11β,21-dihydroxy-16α,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione、11β,21-dihydroxy-16α,17-isopropylidenedioxypregna-1,4-diene-3,20-dione、11β,21-dihydroxy-16α,17α-isopropylidenedioxypregna-1,4-diene-3,20-dione + [14] |
靶点 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H32O6 |
InChIKeyWBGKWQHBNHJJPZ-LECWWXJVSA-N |
CAS号638-94-8 |
关联
31
项与 地奈德 相关的临床试验地奈德洗剂生物等效性研究与人体药代动力学对比研究
地奈德乳膏人体药代动力学对比研究
地奈德乳膏人体生物等效性研究
100 项与 地奈德 相关的临床结果
登录后查看更多信息
100 项与 地奈德 相关的转化医学
登录后查看更多信息
100 项与 地奈德 相关的专利（医药）
登录后查看更多信息
222
项与 地奈德 相关的文献（医药）2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
A pediatric case of dupilumab-induced pustular psoriasis
Article
作者: Dang, Nan ; Zheng, Huiwen ; Ren, Yunqing
Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.We report a 4-year-old boy with AD who developed pustular psoriasis during treatment with dupilumab.Pustular psoriasis appeared within 1 week of treatment and worsened in the second week. After stopping dupilumab administration, topical corticosteroids (desonide and mometasone furoate creams) and oral desloratadine without relief. Pustular psoriasis was confirmed by pathological examination, and thiamphenicol was administered. After 2 weeks of treatment, the lesions nearly resolved without recurrence in 1-year follow-up.Dupilumab-induced pustular psoriasis is rare in children.
2024-10-01Ophthalmology and Therapy
Correction: Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment
作者: Genovese, Paola ; Gagliano, Caterina ; Dammino, Edoardo ; D’Esposito, Fabiana ; Postorino, Elisa Imelde ; Giannaccare, Giuseppe ; Mazzone, Maria Grazia ; D'Esposito, Fabiana ; Aragona, Pasquale ; Civiale, Claudine
2024-10-01Ophthalmology and Therapy
Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment
Article
作者: Genovese, Paola ; Gagliano, Caterina ; Dammino, Edoardo ; Postorino, Elisa Imelde ; Giannaccare, Giuseppe ; Aragona, Pasquale ; D'Esposito, Fabiana ; Mazzone, Maria Grazia ; Civiale, Claudine
INTRODUCTION:
Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.
METHODS:
This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported outcomes, clinical performance, and safety.
RESULTS:
Thirty patients were enrolled (21 women, 9 men) with a mean age of 61.10 ± 14.53 years. The instillation of the study formulation was associated with a significant reduction in redness scores after 1 month of treatment compared to baseline (mean - 0.51 ± 0.51; p ≤ 0.0001). Although the primary endpoint was not completely met, a 50% reduction in the conjunctival hyperemia index was achieved in 23% of the participants, and 77% showed a reduction of 26% of the same index. In addition, the ophthalmic solution significantly increased tear film break-up time, and a significant reduction of corneal and conjunctival staining with fluorescein was achieved. It also reduced DED symptoms and had a very good safety profile.
CONCLUSIONS:
the study formulation produced a significant improvement in the signs, symptoms, and QoL of patients with mild to moderate DED with a good safety profile after 1 month of treatment.
100 项与 地奈德 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 1974-11-01 | |
| 皮炎 | 美国 | 1972-01-04 | |
| 瘙痒 | 美国 | 1972-01-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用